Latest medical news · page 105

Deadline extended! Answer ACP MKSAP questions and earn a chance to win a free subscription

Mechanical Leaflet Splitting is Feasible in High-Risk Patients Undergoing Valve-in-Valve TAVR

Mechanical leaflet splitting in patients with anatomically high-risk undergoing valve-in-valve (ViV) TAVR saw high procedural success, according to a study published June 25 in JACC: Cardiovascular Interventions.

FDA Approves New Treatment to Reduce Proteinuria in Adults with Primary Immunoglobulin A Nephropathy

The U.S. Food and Drug Administration (FDA) has approved Trutakna (atacicept-vymj) to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression.

Caidya and Simbec-Orion unite in global CRO combo

Contract research organizations (CROs) Caidya and Simbec-Orion have united to create a new platform aimed at helping drug development programs accelerate and scale.

AdaptHealth discloses patient data was stolen in cyberattack

The medical device supplier said that a threat actor accessed company systems through a social engineering attack.

Insulet launches Omnipod 5 in Spain

A high rate of continuous glucose monitor adoption and low level of automated insulin delivery system penetration make Spain an attractive market for Insulet.

Top diabetes tech stories from the first half of 2026

Diabetes technology news has been off to a fast start this year. Here are some highlights of MedTech Dive’s coverage from 2026.

UPDATE: Class 4 Medicines Defect Notification: Relonchem Limited, Gabapentin Relonchem 50mg/ml Oral Solution, EL(26)A/31

Relonchem Limited have informed the MHRA that particles have been observed inside some bottles of Gabapentin Relonchem Oral Solution, identified through a customer complaint.

The AI Use Case That Healthcare is Overlooking

AI performs best where a problem is well-defined, data-intensive, repetitive and operates at a scale that exceeds human tracking capacity. The supply chain hits all four. The post The AI Use Case That Healthcare is Overlooking appeared first on MedCity News .

ACCEL Lite: Cardiorenal Outcomes with Tirzepatide Compared with Dulaglutide in Patients with Diabetes and CVD

In this interview, Matthew Martinez, MD, FACC and Steven E. Nissen, MD, MACC examine the SURPASS-CVOT Randomized Clinical Trial.

New heart disease and strokes plan to save thousands of lives

National framework launched to help reduce premature deaths from heart disease and strokes by a quarter over the next decade.

Hypertension and diabetes prevalence, associated factors, care cascade, and quality of life in older adults: A cross-sectional population-based study in The Gambia, South Africa, and Zimbabwe

by Anthony Muchai Manyara, Suad Abdullah, Ayaan Balshaf, Tadios Manyanga, Momodou Jallow, Etheldreda I. Yoliswa Madela, Hannah Wilson, Anya Burton, Farhanah Paruk, Chris Grundy, Camille Pearse, Tafadzwa Madanhire, Lucy Gates, Bilkish Cassim, Rashida A. Ferrand, Kate A. Ward, Celia L. Gregson Background Hypertension and diabetes prevalence are increasing across Africa. We investigated the prevalence, associated factors, achievement of stages within the care cascade (diagnosis, treatment, control), and health-related quality of life (HRQoL) in three countries in Africa. Methods and findings This…

Post-stroke acute heart failure in patients with large vessel occlusion undergoing endovascular treatment: A pooled analysis of individual patient data from multicenter studies with mediation analysis

by Liyuan Chen, Jiaxing Song, Changwei Guo, Linyu Li, Tao Xu, Chen Gong, Liping Huang, Shuyu Jiang, Lin Gao, Xinyu Li, Gang Wu, Xue Wang, Thanh N. Nguyen, Jeffrey L. Saver, Yangmei Chen, Wenjie Zi, Chang Liu Background Cardiac complications rank among the leading contributors to poor outcomes in ischemic stroke patients along with the neurological impairment, while the risk stratification and prognostic significance of post-stroke acute heart failure (PSHF) remain poorly characterized. This study aimed to investigate the incidence, predictors, and impacts of PSHF in patients with large vessel…

The Foundation Is Built — Now We Must Secure the Future of Interoperability

Patients, providers, and innovators all benefit from secure, trusted, nationwide data exchange. But this trust cannot sustain itself on fragmented governance or competitive enforcement dynamics. The post The Foundation Is Built — Now We Must Secure the Future of Interoperability appeared first on MedCity News .

MeiraGTx scores $400M from Oberland Capital to help get 2 gene therapies to commercialization

As MeiraGTx lines up the pieces for a commercial push, the company has new funding to work with.

The Truth About Testosterone in Women: What Medicine Has Overlooked

Testosterone is not just a “male hormone.” Women need it too. And pretending otherwise has left countless women struggling through midlife while being told everything looks “normal.” The post The Truth About Testosterone in Women: What Medicine Has Overlooked appeared first on MedCity News .

Research: Technical annex: cardiovascular disease modern service framework

Sets out supporting evidence to supplement the cardiovascular disease modern service framework.

Policy paper: Cardiovascular disease modern service framework

Sets out the government’s 10-year strategic vision for the health and care system to reduce premature deaths from heart disease and stroke in England.

MIDD Paired Meeting Program Frequently Asked Questions

MIDD Pilot Program Frequently Asked Questions (FAQs)

Model-Informed Drug Development Paired Meeting Program

FDA is conducting a MIDD Pilot Program to facilitate the development and application of exposure-based, biological, and statistical models derived from preclinical and clinical data sources, referred to as MIDD approaches.

EMA fast tracks review of a medicine for metastatic pancreatic cancer

EMA’s human medicines committee (CHMP) has started a phased review of data on daraxonrasib, a medicine intended for the treatment of metastatic pancreatic cancer. A phased…

FDA approves Trutakna (atacicept-vymj)

Original biologic license approval. injectable, subcutaneous. Sponsor: Vera Therapeutics Inc.

FDA expands Ryaltris (mometasone furoate, olopatadine hydrochloride) approval

Efficacy supplement (new or revised indication). spray, metered, nasal. Sponsor: Glenmark Speclt

Field Safety Notices: 29 June to 03 July 2026

List of Field Safety Notices from 29 June to 03 July 2026